Xiaohu Deng
Directeur Technique/Scientifique/R&D chez Vividion Therapeutics, Inc.
Profil
Xiaohu Deng is currently the Head-Technical Operations at Vividion Therapeutics, Inc. Prior to this, he worked as the Senior Director & Head-CMC at Kura Oncology, Inc. and as the Senior Vice President-Product Development at Viracta Therapeutics, Inc. Deng holds a doctorate degree from Emory University and undergraduate and graduate degrees from Fudan University.
Postes actifs de Xiaohu Deng
| Sociétés | Poste | Début |
|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Xiaohu Deng
| Sociétés | Poste | Fin |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | - |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Xiaohu Deng
| Emory University | Doctorate Degree |
| Fudan University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
